deltatrials
Unknown OBSERVATIONAL NCT03838588

The Tracking Molecular Evolution for NSCLC (T-MENC) Study

Tracking Genomic Cancer Evolution in Patients for Stage IB,II and IIIA Non-small Cell Lung Cancer After Radical Resection: The Tracking Molecular Evolution for NSCLC (T-MENC) Study

Sponsor: Geneplus-Beijing Co. Ltd.

Conditions Adenocarcinoma of Lung Lung Cancer Lung Neoplasms Nonsmall Cell Lung Cancer
Updated 7 times since 2019 Last updated: Feb 10, 2019 Started: Nov 6, 2018 Primary completion: Dec 31, 2021 Completion: Dec 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Adenocarcinoma of Lung and Lung Cancer, this trial is ongoing. The trial is conducted by Geneplus-Beijing Co. Ltd. and has accumulated 7 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2019 – ~Nov 2020 · 20 months · monthly snapshotRecruiting~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotRecruiting~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotRecruiting~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshotRecruiting~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown

    Status: Unknown Status → Unknown

  3. Jan 2022 — Jul 2024 [monthly]

    Unknown Status

    Status: Recruiting → Unknown Status

  4. Dec 2021 — Jan 2022 [monthly]

    Recruiting

  5. Jan 2021 — Dec 2021 [monthly]

    Recruiting

▶ Show 2 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Recruiting

  2. Mar 2019 — Nov 2020 [monthly]

    Recruiting

    First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Geneplus-Beijing Co. Ltd.
  • Xuanwu Hospital, Beijing
Data source: Geneplus-Beijing Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations